teicoplanin

Teicoplanin is a glycopeptide antibiotic produced by fermentation of Actinoplanes teichomyceticus. It is primarily used to treat serious infections caused by Gram-positive bacteria, especially those resistant to beta-lactam antibiotics such as penicillins and cephalosporins. Its mechanism of action involves inhibition of bacterial cell wall synthesis by binding specifically to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors, thereby blocking peptidoglycan polymerization and cross-linking. Teicoplanin exhibits bactericidal activity against a broad range of aerobic and anaerobic Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci, Streptococcus species, Enterococcus faecalis (some strains), Corynebacterium species, Clostridium difficile, and others. It has a long half-life and can be administered intravenously or intramuscularly[1][2][5][7].

Brand names

TargocidTeicomid他格适加立信

Other names

替考拉宁テイコプラニン壁霉素肽可霉素